Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells.
about
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccineNasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.Modulation of viral immunoinflammatory responses with cytokine DNA administered by different routesImmunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice.Recent progress in herpes simplex virus immunobiology and vaccine researchPan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidatesTopical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challengeRoles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models.Effects of the route of infection on immunoglobulin G subclasses and specificity of the reovirus-specific humoral immune response.Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.CD4(+) T cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability.Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptorProphylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virusOverexpression of interleukin-15 compromises CD4-dependent adaptive immune responses against herpes simplex virus 2Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice.Immunomodulation by mucosal gene transfer using TGF-beta DNA.Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.Immune response of T cells during herpes simplex virus type 1 (HSV-1) infection.CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G).Natural killer cells as novel helpers in anti-herpes simplex virus immune response
P2860
Q21089976-976A74C4-A9F5-4112-BA53-BA97317EF318Q33725145-BFCD18C8-DE0F-41D4-8BCE-68FEE2C06F98Q33784988-4DDA7E32-9210-4800-B51F-75DE78DC0A1CQ33785966-D1F9BAA4-114C-45CC-8B95-FDBDD8D62B1DQ33900378-A80D8313-ABAD-41EC-B391-CFCA150224DDQ33963713-1B962203-004A-4D81-B5E4-74DB6A30ABD2Q34350019-9D4F5EB1-808C-4750-AEDA-C4CE940E029BQ34647668-2878FB1E-42C1-47A4-94AA-720C155345BFQ34992660-5A9806C0-3246-4E56-A18E-2A1B66A3FEC3Q35853041-4EFCA873-48E9-4496-A8BF-A0DF17A5709BQ35867962-17A9EAD7-BB1B-401D-B106-5674250C31D4Q35881308-41B66D75-DA3D-4F6E-A2AA-CEA8985DCE9FQ35882585-691812A7-5995-451A-8B3E-DBE2ABAB5BFCQ36086635-A22AD88E-3440-4878-9476-7529EF4977BFQ36368586-9D3D1F7D-4C30-47D0-B493-77563D10C752Q36689912-1D8490AC-C71D-43E1-B6B0-FA8D6F56ACBEQ36879345-15FEE97E-7362-4D13-9CD0-D4E2B10DA929Q37033348-6D2010D3-1A9A-4538-87BC-226ABD708DE1Q37255619-23CD954E-B2DD-4988-9011-AF6BB33E2245Q37383991-4C408451-A03E-4CC0-B35A-825F853BBB72Q37456642-F38D97D3-25AE-4A59-B082-76A39CEA8C2FQ39221171-D17EB255-7436-4F73-9815-F1EB555E80DAQ39685973-D36A9621-D37A-4FE0-BE10-7482CEE51D4DQ39948866-BF479678-BBDD-4A53-BC7E-FD6E42AB2F5A
P2860
Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Vaccination with recombinant v ...... rus through CD4+ Th1+ T cells.
@ast
Vaccination with recombinant v ...... rus through CD4+ Th1+ T cells.
@en
type
label
Vaccination with recombinant v ...... rus through CD4+ Th1+ T cells.
@ast
Vaccination with recombinant v ...... rus through CD4+ Th1+ T cells.
@en
prefLabel
Vaccination with recombinant v ...... rus through CD4+ Th1+ T cells.
@ast
Vaccination with recombinant v ...... rus through CD4+ Th1+ T cells.
@en
P2093
P2860
P1433
P1476
Vaccination with recombinant v ...... rus through CD4+ Th1+ T cells.
@en
P2093
E Manickan
M Dewerchin
M Francotte
P2860
P304
P407
P577
1995-08-01T00:00:00Z